Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Our immune systems rely on iron to function, but so do invading viruses and bacteria. New research from Binghamton University ...

Positive HIV status as well as socioeconomic disadvantages, not breastfeeding, are associated with infant length and birth ...

Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Mortality rates among patients with GCA in Spain are similar to that of the general population, with older age and male sex linked to higher mortality.

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

Agios Pharmaceuticals (AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to less than18 years with PK ...

Blood tests are a routine part of your prenatal care. Here's everything you need to know about what you can expect.

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in ...

SSM Health Cardinal Glennon Children's Hospital partners with Eye See Me African Bookstore to provide books promoting ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...